WaveMan
WaveMan · Company
KRYS · Krystal Biotech, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KRYS Krystal Biotech (KRYS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001711279
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
273
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $179.2K priced

What the filings say about KRYS

Insiders, 180 days
-$42.1M net sold
4 sellers · 45% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$26.9M
3 notices

Krystal Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Krystal Biotech, Inc. insiders sold a net $42.1M of stock across 476 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Krishnan Krish S
President and CEO
SELL
2026-09-04 SEC
520
$184.4K
-10.7%
Context
  • 176 earlier Form 4 trades (code P or S) here by this insider (176 sales), the last on Jun 4, 2026.
  • The trade is 0.0% of the 1,372,023 shares held after it.
  • 2 other insiders sold within 30 days.
  • 273 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Krishnan Krish S sold about $184.4K of KRYS under a 10b5-1 plan on Sep 4, 2026; 2 other insiders sold within 30 days and 273 funds added in the latest 13F quarter.
Krishnan Krish S
President and CEO
SELL
2026-09-04 SEC
2,029
$721.5K
-10.7%
Context
  • 176 earlier Form 4 trades (code P or S) here by this insider (176 sales), the last on Jun 4, 2026.
  • The trade is 0.1% of the 1,369,994 shares held after it.
  • 2 other insiders sold within 30 days.
  • 273 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Krishnan Krish S sold about $721.5K of KRYS under a 10b5-1 plan on Sep 4, 2026; 2 other insiders sold within 30 days and 273 funds added in the latest 13F quarter.
Krishnan Krish S
President and CEO
SELL
2026-09-04 SEC
3,297
$1.2M
-10.7%
Context
  • 176 earlier Form 4 trades (code P or S) here by this insider (176 sales), the last on Jun 4, 2026.
  • The trade is 0.2% of the 1,366,697 shares held after it.
  • 2 other insiders sold within 30 days.
  • 273 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Krishnan Krish S sold about $1.2M of KRYS under a 10b5-1 plan on Sep 4, 2026; 2 other insiders sold within 30 days and 273 funds added in the latest 13F quarter.
Krishnan Krish S
President and CEO
SELL
2026-09-04 SEC
3,981
$1.4M
-10.7%
Context
  • 176 earlier Form 4 trades (code P or S) here by this insider (176 sales), the last on Jun 4, 2026.
  • The trade is 0.3% of the 1,362,716 shares held after it.
  • 2 other insiders sold within 30 days.
  • 273 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Krishnan Krish S sold about $1.4M of KRYS under a 10b5-1 plan on Sep 4, 2026; 2 other insiders sold within 30 days and 273 funds added in the latest 13F quarter.
Krishnan Krish S
President and CEO
SELL
2026-09-04 SEC
3,143
$1.1M
-10.7%
Context
  • 176 earlier Form 4 trades (code P or S) here by this insider (176 sales), the last on Jun 4, 2026.
  • The trade is 0.2% of the 1,359,573 shares held after it.
  • 2 other insiders sold within 30 days.
  • 273 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Krishnan Krish S sold about $1.1M of KRYS under a 10b5-1 plan on Sep 4, 2026; 2 other insiders sold within 30 days and 273 funds added in the latest 13F quarter.
476 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 471 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$42.1M over 180 days
-$26.2M over 90 days · -$33.4M of it by a 10%+ holder
below 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
273 funds bought in last quarter
more than 94% of Pharma & Biotech
Revenue
+33.9% year over year
more than 72% of Pharma & Biotech
Margin
52.6% net margin
more than 95% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.7% of the float short (float per yahoo 2026-10-26) · 11.2 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KRYS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.2%12M
-1%+34%+68%+103%2025-102025-122026-022026-042026-062026-082026-10 2026-06-04 · Krishnan Suma sold $3.9M2026-06-04 · Krishnan Krish S sold $3.5M2026-02-24 · JANNEY DANIEL sold $3.1M2026-02-19 · ROSSI DINO A sold $2.8M2026-02-27 · JANNEY DANIEL sold $2.6M2026-08-14 · ROSSI DINO A sold $2.4M2026-02-24 · JANNEY DANIEL sold $2.4M2026-03-04 · Krishnan Krish S sold $2.3M2025-12-04 · Krishnan Suma sold $2.3M2025-12-04 · Krishnan Krish S sold $2.3M2025-12-04 · Krishnan Suma sold $2.3M2025-12-04 · Krishnan Krish S sold $2.3M2026-02-19 · ROSSI DINO A sold $2.1M2026-02-24 · JANNEY DANIEL sold $1.8M2026-08-14 · ROSSI DINO A sold $1.7M2026-08-14 · ROSSI DINO A sold $1.6M2026-03-04 · Krishnan Suma sold $1.6M2026-02-09 · ROMANO KATHRYN sold $1.5M2026-06-04 · Krishnan Krish S sold $1.5M2026-09-04 · Krishnan Krish S sold $1.4M2026-09-04 · Krishnan Suma sold $1.4M2026-02-26 · JANNEY DANIEL sold $1.4M2026-03-04 · Krishnan Suma sold $1.3M2025-12-04 · Krishnan Krish S sold $1.2M2025-12-04 · Krishnan Suma sold $1.2M2026-09-04 · Krishnan Suma sold $1.2M2026-09-04 · Krishnan Krish S sold $1.2M2025-12-04 · Krishnan Suma sold $1.2M2025-12-04 · Krishnan Krish S sold $1.2M2026-09-04 · Krishnan Krish S sold $1.2M2026-06-04 · Krishnan Suma sold $1.2M2026-09-04 · Krishnan Suma sold $1.2M2026-02-24 · JANNEY DANIEL sold $1.2M2026-09-04 · Krishnan Suma sold $1.1M2026-09-04 · Krishnan Krish S sold $1.1M2026-02-24 · JANNEY DANIEL sold $1.1M2026-08-14 · ROSSI DINO A sold $1.0M2026-03-04 · Krishnan Suma sold $954.8K2026-02-24 · JANNEY DANIEL sold $942.9K2026-06-04 · Krishnan Suma sold $868.2K2026-06-04 · Krishnan Krish S sold $861.6K2026-09-04 · Krishnan Suma sold $836.3K2026-09-04 · KRISH KRISHNAN filed to sell $9.3M2026-09-04 · SUMA KRISHNAN filed to sell $9.3M2026-08-14 · Dino A. Rossi filed to sell $8.3M2026-06-25 · Thomas John Charles filed to sell $347.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KRYS: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
4,418,197 sh
$1.6B
BlackRock, Inc.
4,181,432 sh
$1.6B
Avoro Capital Advisors LLC
2,888,888 sh
$1.1B
VANGUARD PORTFOLIO MANAGEMENT LLC
1,574,905 sh
$585.3M
STATE STREET CORP
1,351,158 sh
$502.2M

Congress trades in KRYS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KRYS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
KRISH KRISHNAN
Filed 2026-09-04
$9.3M
SUMA KRISHNAN
Filed 2026-09-04
$9.3M
Dino A. Rossi
Filed 2026-08-14
$8.3M
Thomas John Charles
Filed 2026-06-25
$347.3K

KRYS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Biotechnology Portfolio
$557.1M position · as of 2026-05-31
10.6%
Franklin Genomic Advancements ETF
$1.8M position · as of 2026-06-30
6.3%
Biondo Focus Fund
$2.2M position · as of 2026-06-30
4.9%
Invesco S&P SmallCap Health Care ETF
$5.6M position · as of 2026-05-31
4.3%
First Trust NYSE Arca Biotechnology Index Fund
$108.9M position · as of 2026-06-30
3.9%
CapForce IBD 50 ETF
$1.6M position · as of 2026-07-31
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 10 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
3 active
1
Phase 2
0 active
3
Phase 3
1 active
1
Early Phase 1
1 active
1
Not applicable
1 active
5
Multi-phase
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Krishnan
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.4M
$22.8M
$4.6M
+311%
+20%
2024
$15.6M
$19.8M
$5.6M
+183%
+14%
2023
$6.2M
$11.7M
$2.9M
+124%
+15%
2022
$3.3M
$4.3M
$2.8M
+43%
+11%
2021
$7.4M
$6.8M
$5.9M
+26%
+25%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $42.1M sold by insiders over 180 days, 273 funds added last quarter, $26.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KRYS financials

Revenue growth
+33.9%
XBRL, annual
Net margin
52.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$440.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+54.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$257.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2017-08-08 (108 months older than the period end); equity 2026-06-30
Cash flow to debt
64.02x
TTM operating cash flow over long-term debt only, 2017-08-08 (108 months older than the period end)
Return on equity
+20.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+18.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -7%, not meaningful
Return on capital employed
+16.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
39.31x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$8.9B
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term debt only, 2017-08-08 (108 months older than the period end), minus cash 2026-06-30
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.64x
P/E over trailing EPS growth of 62%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$389.1M$290.5M$50.7M$0
Operating income$161.3M$65.7M-$109.6M-$145.2M
Net income$204.8M$89.2M$10.9M-$140.0M
EPS (diluted)6.843.000.39-5.49
Operating cash flow$200.9M$123.4M-$88.8M-$100.6M
Cash$496.3M$344.9M$358.3M$161.9M
SEC XBRL, fiscal years, as known on 2026-10-28

KRYS Stock Sonar score 6/7 axes

Find similar shapesCompare

KRYS ranks highest on institutional and government (94th percentile) and profitability (91st), and lowest on insider conviction (4th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
91
Inputs
  • Return on equity+20.1% · 88 pct, sector of 545
  • Return on assets+18.3% · 92 pct, sector of 691
  • Return on invested capitaleffective tax rate -7%, not meaningful
  • Return on capital employed+16.3% · 93 pct, sector of 576
Financial health
90
Inputs
  • Debt to equity0.00x · 82 pct, sector of 352
  • Cash flow to debt64.02x · 99 pct, sector of 371
Growth
72
Inputs
  • Revenue growth, YoY+33.9% · 72 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$24.2M · 9 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
94
Inputs
  • Funds adding, latest quarter273 · 94 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
45
Inputs
  • Short interest, % of float+14.7% · 26 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.2% · 63 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KRYS filings, in plain words

Are Krystal Biotech insiders buying or selling KRYS?

In the 180 days to 2026-10-28, Krystal Biotech insiders were net sellers, a net $42.1M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of KRYS?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $26.9M of stock; the latest, by KRISH KRISHNAN, was filed 2026-09-04.

Read the full summary

In the 180 days to 2026-10-28, Krystal Biotech insiders were net sellers of KRYS, a net $42.1M across purchases and sales reported on Form 4 by 4 sellers. Most of that figure, $33.4M, came from a holder of 10% or more rather than an officer or director. 45% of the 58 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $26.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies